EP1236394B1 - Procédé de culture d'acariens, préparation nutritive pour ce procédé, et préparation d'extraits allergéniques à partir de ces acariens - Google Patents
Procédé de culture d'acariens, préparation nutritive pour ce procédé, et préparation d'extraits allergéniques à partir de ces acariens Download PDFInfo
- Publication number
- EP1236394B1 EP1236394B1 EP02290444A EP02290444A EP1236394B1 EP 1236394 B1 EP1236394 B1 EP 1236394B1 EP 02290444 A EP02290444 A EP 02290444A EP 02290444 A EP02290444 A EP 02290444A EP 1236394 B1 EP1236394 B1 EP 1236394B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino acids
- medium according
- culture
- medium
- mites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 241000238876 Acari Species 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000002009 allergenic effect Effects 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000284 extract Substances 0.000 title description 10
- 241000238711 Pyroglyphidae Species 0.000 title 1
- 229940046533 house dust mites Drugs 0.000 title 1
- 230000000384 rearing effect Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 241000282414 Homo sapiens Species 0.000 claims abstract description 16
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 claims abstract description 8
- 241000238557 Decapoda Species 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 235000013601 eggs Nutrition 0.000 claims abstract description 6
- 241000536435 Blomia <angiosperm> Species 0.000 claims abstract description 5
- 241000238713 Dermatophagoides farinae Species 0.000 claims abstract description 5
- 102000011782 Keratins Human genes 0.000 claims abstract description 5
- 108010076876 Keratins Proteins 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000000470 constituent Substances 0.000 claims abstract description 4
- 244000068988 Glycine max Species 0.000 claims abstract 4
- 235000010469 Glycine max Nutrition 0.000 claims abstract 4
- 238000012258 culturing Methods 0.000 claims abstract 3
- 238000001228 spectrum Methods 0.000 claims abstract 3
- 229940024606 amino acid Drugs 0.000 claims description 52
- 235000001014 amino acid Nutrition 0.000 claims description 52
- 239000002609 medium Substances 0.000 claims description 29
- 235000018102 proteins Nutrition 0.000 claims description 15
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 13
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 241000209140 Triticum Species 0.000 claims description 8
- 235000021307 Triticum Nutrition 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 7
- 239000011666 cyanocobalamin Substances 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- 229930182844 L-isoleucine Natural products 0.000 claims description 5
- 239000004395 L-leucine Substances 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930182821 L-proline Natural products 0.000 claims description 5
- 229960003767 alanine Drugs 0.000 claims description 5
- 229960005261 aspartic acid Drugs 0.000 claims description 5
- 229960002885 histidine Drugs 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- 229960003136 leucine Drugs 0.000 claims description 5
- 229960002429 proline Drugs 0.000 claims description 5
- 229960004799 tryptophan Drugs 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 239000011665 D-biotin Substances 0.000 claims description 4
- 235000000638 D-biotin Nutrition 0.000 claims description 4
- 241000238741 Euroglyphus maynei Species 0.000 claims description 4
- 235000019766 L-Lysine Nutrition 0.000 claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- 229960003646 lysine Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- 235000019393 L-cystine Nutrition 0.000 claims description 3
- 239000004158 L-cystine Substances 0.000 claims description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- 235000013878 L-cysteine Nutrition 0.000 claims description 2
- 239000004201 L-cysteine Substances 0.000 claims description 2
- 229960002433 cysteine Drugs 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000000428 dust Substances 0.000 claims 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- 210000004207 dermis Anatomy 0.000 claims 2
- LYRJFGBVBBMYQA-FNWDONPISA-N (2S)-2-aminobutanedioic acid (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid (2S)-2-aminopropanoic acid (2R)-2-amino-3-sulfanylpropanoic acid Chemical compound C[C@H](N)C(O)=O.SC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N LYRJFGBVBBMYQA-FNWDONPISA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- XXPMADSNSNYGFV-ZMTAAGTBSA-N N[C@@H](C(C)C)C(=O)O.N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O.N[C@@H](CC1=CC=C(C=C1)O)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@@H](CO)C(=O)O.N1[C@H](C(=O)O)CCC1.N[C@@H](CC1=CC=CC=C1)C(=O)O.N[C@@H](CCSC)C(=O)O.N[C@@H](CCCCN)C(=O)O.N[C@@H](CC(C)C)C(=O)O.N[C@@H]([C@@H](C)CC)C(=O)O.N[C@@H](CC1=CNC=N1)C(=O)O Chemical compound N[C@@H](C(C)C)C(=O)O.N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O.N[C@@H](CC1=CC=C(C=C1)O)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@@H](CO)C(=O)O.N1[C@H](C(=O)O)CCC1.N[C@@H](CC1=CC=CC=C1)C(=O)O.N[C@@H](CCSC)C(=O)O.N[C@@H](CCCCN)C(=O)O.N[C@@H](CC(C)C)C(=O)O.N[C@@H]([C@@H](C)CC)C(=O)O.N[C@@H](CC1=CNC=N1)C(=O)O XXPMADSNSNYGFV-ZMTAAGTBSA-N 0.000 claims 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001033 granulometry Methods 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 238000000227 grinding Methods 0.000 abstract description 3
- 210000000434 stratum corneum Anatomy 0.000 abstract description 3
- 241000123966 Blomia tropicalis Species 0.000 abstract 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 7
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 7
- 229960002104 cyanocobalamin Drugs 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- -1 acids amines Chemical class 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- PLHNNMDRJIUFMN-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;hypochlorous acid Chemical compound ClO.SC[C@H](N)C(O)=O PLHNNMDRJIUFMN-DKWTVANSSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229940068840 d-biotin Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
Definitions
- the present invention relates to a method of culture of mites for the production of extracts allergenic mites, as well as formulations nutritious intended to be used in these processes.
- a method of growing mites is described in US Patent 6129935.
- allergenic extracts used in allergology formulations are used for prepare allergenic extracts used in allergology formulations to serve, for example, in vivo or in vitro allergology tests, or desensitizing preparations administered to patients.
- mites there are in particular the following species: Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia kulagini or tropicalis, Pyroglyphus africanus , and Euroglyphus maynei, which are domestic mites which feed mainly on human dander.
- the present invention therefore proposes to provide a method of growing and producing mites, and in particular mites of the aforementioned species, limiting to maximum risk of presence of infectious agents of animal or human origin.
- Another object of the invention is to provide a such a process which allows a significant yield in mites.
- Yet another object of the invention is possibly improve the antigenicity of mites intended to be used or extracted to form final formulations.
- Yet another object of the invention is to make it easy to remove much of the culture centre.
- the subject of the invention is a method of cultivating and producing mites, and in particular mites belonging to at least one of the following species: Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia kulagini or tropicalis, Pyroglyphus africanus , and Euroglyphus maynei , characterized in that the mites are cultivated on a medium devoid of human or animal elements or proteins and comprising, in effective amounts, a plurality of amino acids in particulate form with a particle size less than 250 ⁇ m, or under lyophilized form.
- the desired particle size of amino acids can be obtained by grinding amino acids, individually or as a mixture.
- the amino acids can be obtained by dissolution of the amino acids, then lyophilization. In this case we prefer that the freeze drying results in particles of size less than 250 ⁇ m.
- the acids may have been ground and / or freeze-dried, in particular according to their physical characteristics, for example their solubility, and, if necessary, certain acids can be added as is in the mixture.
- the invention is based on the discovery that, if one use as is (without grinding and / or without solubilization-lyophilization and / or without the addition of salts) commercially available amino acids, mites are extremely poorly cultivated and yields are very weak. Surprisingly, the mixtures amino acids with the characteristics defined in the invention result in comparable yields or even higher than conventional yields using human dander.
- Amino acid mixtures include, preferably most or all of the amino acids natural constituents of proteins. Usually hears at least 50%, for example 60 to 80%, of the twenty amino acids that are natural building blocks of proteins or equivalent assimilable amino acids. We can however, also, add non-amino acids or replace some of the amino acids with amino acids that do not constitute proteins.
- the respective proportions of amino acids can approach the quantitative proportions of amino acids in substances such as keratin, or the stratum corneum, shrimp eggs or soy, but a proportionally distributed identity is not in no way required, since the amino acids individual are present in sufficient quantity.
- the nutrient medium which comprises the mixture of acids amines of the process according to the invention can also contain other usual elements of nutrient media for mites, intended either to provide a supplement nutritious, or to give the environment a texture specific to development and multiplication of mites, as well only salts.
- wheat germ and / or yeast especially baker's yeast, and / or cyanocobalamin and / or d-biotin.
- the environment may also include other vitamins.
- the wheat germs are preferably heated to eliminate any risk of allergenicity.
- the medium of culture containing the mixture of amino acids, is brought at a suitable humidity level, usual for mites that we cultivate, and kept at the usual temperature suitable.
- the cultivation times can be, for example, three months and we prefer durations classic from 2 to 5 months.
- the subject of the invention is also the media for culture containing mixtures of amino acids according to the invention.
- Another subject of the invention is the methods of preparations of allergen extracts or formulations obtained from mites cultivated by the process according to the invention.
- This example describes a culture process in a medium containing a commercial preparation of acids amines.
- a culture medium is prepared containing wheat germ, cyanocobalamin, yeast bakery and D-biotin.
- Wheat germs are autoclaved at 121 ° C for 20 'then crushed and sieved on a 250 ⁇ m sieve.
- the cyanocobalamin is ground and sieved on a 250 ⁇ m porosity sieve.
- Baker's yeast is heated to 122 ° C for 2 to 3 ', then between 100 and 135 ° C for 12 "in a drum with a rotation speed of 5 turns per minute, then heated to 100 ° C for 15 '.
- the solution is lyophilized and the lyophilisate harvested is sieved on a vibrating sieve of 250 ⁇ m porosity.
- the medium itself is prepared in the way next :
- the prepared media are seeded with the échantil is classic seed cultures of Dermatophagoides pteronisynus.
- the culture is carried out in flasks at a temperature of 25 ° C, at a humidity level of 75%. The samples are taken at different times.
- the harvested media are then lyophilized and extracted at 5% in ammonium bicarbonate solution 4 g / 1 for 24 hours at + 4 ° C, then centrifuged at 3000 rpm. for 15 min. at + 4 ° C. The supernatant is collected and then filtered on a 0.45 ⁇ m Millex HV filter of porosity (Millipore).
- the activity is measured total allergenic (by Rast-inhibition), proteins (by the Lowry technique and / or the Bradford), and the major allergens Der p 1 and Der p 2 (using standard dosing kits).
- the result of the Rast-inhibition is expressed in IR / ml (IR: reactivity index), the extracts being dosed in comparison with a reference extract of which the activity is 100 IR / ml.
- Example 2 The middle of Example 2 is identical to that of example 1 with the difference that the commercial solution lyophilized amino acid is replaced by a preparation of human dander.
- the dander powder collected is then treated with acetone and left to decant for 24 hours. The supernatant is removed. We then proceed to a final washing operation in acetone. We collect the pellet that we distribute it in thin layers on trays and that it is covered with a perforated aluminum sheet. This substance is dried in a hood then finally sieved with a 250 ⁇ m vibrating screen.
- the culture medium of this example includes 90 g of the aforementioned preparation of human dander.
- the culture medium includes wheat germ, cyanocobalamin and yeast according to examples 1 and 2.
- the solution is then lyophilized and the lyophilisate harvested is sieved on a vibrating sieve of 250 ⁇ m.
- the whole is homogenized and then sieved over 400 ⁇ m. After sowing the culture is carried out as in example 1 and 2.
- Example 1 The comparative results of Examples 1 to 3 appear in Table 1 for a first culture cycle, after 3 months, and in Tables 2 and 3 for a second culture cycle (the mites cultivated on a given medium are reseeded on the same environment), after 2.5 months and 3 months, respectively: Total allergenic activity, protein levels, Der p 1 and Der p 2 in extracts 1/20 Dermatophagoides pteronyssinus cultivated on different media after three months of cultivation.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
- L-alanine 3,8 g
- L-arginine 4,2 g
- acide L-aspartique 5,2 g
- L-cystéine chlorhydrate monohydratée exprimé en L-cystéine/L-cystine 1,7 g
- acide L-glutamique 11,5 g
- glycine 2,7 g
- L-histidine 3,1 g
- L-isoleucine 5,0 g
- L-leucine 6,7 g
- Chlorhydrate de L-Lysine, exprimé en L-lysine 5,0 g
- L-méthionine 2,4 g
- L-phénylalanine 7,0 g
- L-proline 10,3 g
- L-sérine 9,6 g
- L-thréonine 3,8 g
- L-tryptophane 1,3 g
- L-tyrosine 0,6 g
- L-valine 5,5 g
- Chlorure de calcium dihydraté 0,44 g
- Sulfate de magnésium heptahydraté 0,493 g
- Hydroxyde de sodium 2,6 g
- Hydroxide de potassium 0,70 g
- Chlorure de potassium 0,078 g
- L-alanine 17,2 g
- L-arginine 26,4 g
- L-cystéine chlorhydrate monohydratée 4,4 g
- - glycine 49,5 g
- L-histidine 5,2 g
- L-isoleucine 13,2 g
- chlorhydrate de L-Lysine 20,0 g
- L-méthionine 8,0 g
- L-proline 8,8 g
- L-sérine 44,0 g
- L-thréonine 13,6 g
- L-valine 13,6 g
- L-tryptophane 1,3 g
- L-phénylalanine 20,8 g
- L-leucine 34,8 g
- acide L-glutamique 64,4 g
- acide L-aspartique 9,7 g
Activité allergénique totale, taux protéiques, de Der p 1 et de Der p 2 dans les extraits au 1/20ème de Dermatophagoides pteronyssinus cultivé sur différents milieux après trois mois de culture. | |||
Milieu contenant | Acides aminés (exemple 1) | Squames humaines (exemple 2) | Acides aminés (exemple 3) |
Activité allergénique totale (IR/ml) | 263 | 284 | 573 |
Taux protéique(µg/ml ; technique de Bradford) | 537 | 544 | 217 |
Taux protéique (µg/ml ; technique de Lowry) | 5689 | 6446 | 5538 |
Der p 1 (µg/ml) | 187,5 | 231,5 | 69,0 |
Der p 2 (µg/ml) | 2,0 | 2,5 | 10,0 |
Activité allergénique totale, taux protéique, de Der p 1 et de Der p 2 dans les extraits au 1/20ème de Dermatophagoides pteronyssinus cultivé pour un second cycle sur différents milieux après deux mois et demi de culture. | |||
Milieu contenant | Acides aminés (exemple 1) | Squames humaines (exemple 2) | Acides aminés (exemple 3) |
Activité allergénique totale (IR/ml) | 617 | 713 | 195 |
Taux protéique (µg/ml ; technique de Bradford) | 328 | 371 | 75 |
Der p 1 (µg/ml) | 83,0 | 138,0 | 8,5 |
Der p 2 (µg/ml) | 19,5 | 19,5 | 3,0 |
Activité allergénique totale, taux protéique, de Der p 1 et de Der p 2 dans les extraits au 1/20ème de Dermatophagoides pteronyssinus cultivé pour un second cycle sur différents milieux après trois mois de culture. | |||
Milieu contenant | Acides aminés (exemple 1) | Squames humaines (exemple 2) | Acides aminés (exemple 3) |
Activité allergénique totale (IR/ml) | 631 | 486 | 192 |
Taux protéique(µg/ml ; technique de Bradford) | 363 | 411 | 110 |
Der p 1 (µg/ml) | 206,0 | 267,5 | 23,0 |
Der p 2 (µg/ml) | 14,0 | 4,5 | 5,0 |
Claims (18)
- Milieu de culture et de production d'acariens, et notamment d'acariens appartenant à l'une au moins des espèces suivantes : Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia kulagini ou tropicalis, Pyroglyphus africanus, et Euroglyphus maynei, caractérisé en ce qu'il est dépourvu d'éléments ou de protéines humaines ou animales et qu'il comprend, en quantités efficaces, une pluralité d'acides aminés sous forme particulaire avec une granulométrie inférieure à 250 µm ou sous forme lyophilisée.
- Milieu selon la revendication 1, caractérisé en ce qu'il comprend des acides aminés obtenus par un broyage d'acides aminés.
- Milieu selon la revendication 2 caractérisé en ce qu'il comprend également des acides aminés lyophilisés et/ou tels quels du commerce.
- Milieu selon la revendication 1 caractérisé en ce qu'il comprend des acides aminés lyophilisés et des acides aminés tels quels du commerce.
- Milieu selon l'une des revendications 1 à 4 caractérisé en ce qu'il contient des sels.
- Milieu selon l'une des revendications 1 à 5, caractérisé en ce que le mélange d'acides aminés comporte au moins 50% des acides aminés constitutifs naturels des protéines ou leurs équivalents.
- Milieu selon l'une des revendications 1 à 6 caractérisé en ce que le mélange d'acides aminés reproduit le spectre des acides aminés constitutifs de la kératine ou de la couche cornée.
- Milieu selon l'une des revendications 1 à 6, caractérisé en ce que le mélange d'acides aminés reproduit le spectre des acides aminés présents dans les oeufs de crevettes ou dans le soja.
- Milieu selon l'une des revendications 7 et 8 caractérisé en ce que les proportions respectives des acides aminés sont proches des proportions quantitatives des acides aminés et des sels dans des substances telles que la kératine ou la couche cornée ou les oeufs de crevettes ou le soja.
- Milieu selon l'une des revendications 1 à 9, caractérisé en ce qu'il comporte également d'autres éléments usuels de milieux nutritifs pour acariens, destinés à apporter un complément nutritif, et/ou à donner au milieu une texture propre au développement et à la multiplication des acariens.
- Milieu selon la revendication 10, caractérisé en ce qu'il comporte en outre, des germes de blé et/ou de la levure, notamment de la levure de boulangerie, et/ou de la cyanocobalamine et/ou de la d-biotine.
- Milieu selon l'une des revendications 1 à 11, caractérisé en ce qu'il peut contenir du soja.
- Milieu selon l'une des revendications 1 à 12, caractérisé en ce qu'il comporte au moins 50% des acides aminés suivants :L-alanineL-arginineAcide L-aspartiqueL-cystéine/cystineAcide L-glutamiqueglycineL-histidineL-isoleucineL-leucineL-LysineL-méthionineL-phénylalanineL-prolineL-sérineL-thréonineL-tryptophaneL-tyrosineL-valine
- Milieu selon la revendication 13, caractérisé en ce qu'il comprend les acides aminés dans les proportions suivantes, pour un total de 93,711 g :L-alanine 3,8 gL-arginine 4,2 gacide L-aspartique 5,2 gL-cystéine chlorhydrate monohydratée exprimé en L-cystéine/L-cystine 1,7 gacide L-glutamique 11,5 gglycine 2,7 gL-histidine 3,1 gL-isoleucine 5,0 gL-leucine 6,7 gChlorhydrate de L-lysine, exprimé en L-lysine 5,0 gL-méthionine 2,4 gL-phénylalanine 7,0 gL-proline 10,3 gL-sérine 9,6 gL-thréonine 3,8 gL-tryptophane 1,3 gL-tyrosine 0,6 gL-valine 5,5 gChlorure de calcium dihydraté 0,44 gSulfate de magnésium heptahydraté 0,493 gHydroxyde de sodium 2,6 gHydroxide de potassium 0,70 gChlorure de potassium 0,078 g
- Procédé de culture et de production d'acariens, et notamment d'acariens appartenant à l'une au moins des espèces suivantes : Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia kulagini ou tropicalis, Pyroglyphus africanus, et Euroglyphus maynei, caractérisé en ce que l'on cultive les acariens sur un milieu selon l'une quelconque des revendications 1 à 14.
- Procédé selon la revendication 15 caractérisé en ce que le milieu de culture, contenant le mélange d'acides aminés, est amené à un degré d'humidité-convenable, usuel pour les acariens que l'on cultive, et maintenu à la température habituelle convenable.
- Procédé selon l'une des revendications 15 et 16 caractérisé en ce que l'on effectue la culture entre 2 et 5 mois.
- Procédé d'obtention d'une préparation d'allergènes caractérisé en ce que l'on réalise une extraction des allergènes de la culture selon l'une des revendications 15 à 17.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0102835 | 2001-03-01 | ||
FR0102835A FR2821623B1 (fr) | 2001-03-01 | 2001-03-01 | Procede de culture d'acariens, preparation nutritive pour ce procede, et preparation d'extraits allergeniques a partir de ces acariens |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1236394A1 EP1236394A1 (fr) | 2002-09-04 |
EP1236394B1 true EP1236394B1 (fr) | 2003-10-22 |
Family
ID=8860636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02290444A Revoked EP1236394B1 (fr) | 2001-03-01 | 2002-02-22 | Procédé de culture d'acariens, préparation nutritive pour ce procédé, et préparation d'extraits allergéniques à partir de ces acariens |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1236394B1 (fr) |
AT (1) | ATE252314T1 (fr) |
DE (1) | DE60200065T2 (fr) |
DK (1) | DK1236394T3 (fr) |
ES (1) | ES2208627T3 (fr) |
FR (1) | FR2821623B1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008119762A1 (fr) | 2007-03-30 | 2008-10-09 | Alk-Abelló A/S | Procédé de production d'acariens |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011151449A1 (fr) | 2010-06-03 | 2011-12-08 | Alk-Abelló A/S | Produit pharmaceutique comprenant un ou plusieurs extraits d'allergène de larve d'acarien et méthode de fabrication dudit produit pharmaceutique |
CN104285912A (zh) * | 2014-10-23 | 2015-01-21 | 中国农业科学院蔬菜花卉研究所 | 一种室内快速扩繁叶螨种群的方法 |
CN105831023A (zh) * | 2016-06-14 | 2016-08-10 | 福建省农业科学院食用菌研究所 | 一种长头螨的培育方法 |
CN111543397A (zh) * | 2020-06-23 | 2020-08-18 | 安徽国际旅行卫生保健中心(合肥海关口岸门诊部) | 一种腐食酪螨的快速增殖培养方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6129935A (en) * | 1998-05-15 | 2000-10-10 | Entomos, Llc | Methods for rearing insects, mites, and other beneficial organisms |
-
2001
- 2001-03-01 FR FR0102835A patent/FR2821623B1/fr not_active Expired - Fee Related
-
2002
- 2002-02-22 EP EP02290444A patent/EP1236394B1/fr not_active Revoked
- 2002-02-22 DK DK02290444T patent/DK1236394T3/da active
- 2002-02-22 ES ES02290444T patent/ES2208627T3/es not_active Expired - Lifetime
- 2002-02-22 AT AT02290444T patent/ATE252314T1/de active
- 2002-02-22 DE DE60200065T patent/DE60200065T2/de not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008119762A1 (fr) | 2007-03-30 | 2008-10-09 | Alk-Abelló A/S | Procédé de production d'acariens |
US8312841B2 (en) | 2007-03-30 | 2012-11-20 | Alk-Abello A/S | Method for mite production |
Also Published As
Publication number | Publication date |
---|---|
ATE252314T1 (de) | 2003-11-15 |
FR2821623A1 (fr) | 2002-09-06 |
FR2821623B1 (fr) | 2003-05-30 |
DE60200065D1 (de) | 2003-11-27 |
DK1236394T3 (da) | 2004-02-23 |
DE60200065T2 (de) | 2004-07-22 |
ES2208627T3 (es) | 2004-06-16 |
EP1236394A1 (fr) | 2002-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1101695C (zh) | 植物提取物用于制备治疗骨吸收增加性疾病的药物的用途及其组合物 | |
CN1761662A (zh) | 能促进i型胶原蛋白和/或弹力蛋白产生的组合物 | |
WO2021205420A1 (fr) | Compositions comprenant des algues et leurs méthodes d'utilisation pour augmenter la production de produit animal | |
BRPI0808333B1 (pt) | Extrato bacteriano para doenças respiratórias e processo para sua preparação | |
JP2021169540A (ja) | 上皮組織におけるバリア欠陥を伴う疾患の予防または治療において使用するための適合溶質または溶質混合物 | |
Chen et al. | Picochlorum as an alternative to Nannochloropsis for grouper larval rearing | |
CN1070056C (zh) | 一种制备含有杀死的酪酸梭状芽孢杆菌种细菌的微生物细胞的粉末组合物的方法 | |
CN1169774C (zh) | 具有改进水溶性的蜂胶提取物及制备方法和组合物 | |
WO2003070921A1 (fr) | PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT | |
EP1236394B1 (fr) | Procédé de culture d'acariens, préparation nutritive pour ce procédé, et préparation d'extraits allergéniques à partir de ces acariens | |
JP6038486B2 (ja) | 台湾グリーンプロポリス抽出物を含む薬剤および栄養補給剤 | |
FR2537436A1 (fr) | Procede de regulation de l'appetit et de l'efficacite de l'utilisation des aliments utilisant de l'interferon | |
CN1589889A (zh) | 霍山石斛萃取物,其制备方法及应用 | |
JP6741280B2 (ja) | Ace阻害、血圧上昇抑制、又は血圧降下に用いられる組成物、及びその製造方法 | |
US20030059445A1 (en) | Process for cultivating mites, nutrient preparation for this process, and preparation of allergenic extracts from these mites | |
FR2615737A1 (fr) | Preparation et utilisation d'interferon-gamma | |
KR100249913B1 (ko) | 클로렐라 배양 방법 | |
JP6674241B2 (ja) | 認知機能の維持または改善剤 | |
KR20110010957A (ko) | 저온에서 액상으로 효소 추출하는 누에 등의 유효성분 추출방법 및 그 추출물 | |
KR20170096842A (ko) | 불가사리로부터 피부 재생 인자 및 세포 성장 인자의 추출 방법 및 이의 응용 | |
KR20210068848A (ko) | 배스 추출물을 포함하는 동물용 사료 조성물 및 이의 제조방법 | |
JPH0967265A (ja) | 魚類病原ウイルスに対する抗ウイルス剤 | |
US20060073167A1 (en) | Vaccine for fish cold-water disease | |
JPS60149393A (ja) | トコフエロ−ルの製造法 | |
Slamet et al. | ADDITION OF ECO-ENZYME IN DIFFERENT MAINTENANCE MEDIA ON POPULATION AND GROWTH OF MAGGOT (HERMATIA ILLUCENS) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17P | Request for examination filed |
Effective date: 20021007 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031022 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031022 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031022 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031022 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031022 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: FRENCH |
|
REF | Corresponds to: |
Ref document number: 60200065 Country of ref document: DE Date of ref document: 20031127 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040122 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040122 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20040115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040222 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040228 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2208627 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: ALK-ABELLO A/S Effective date: 20040722 Opponent name: CITEQ B.V. Effective date: 20040722 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040322 |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: CITEQ B.V. Effective date: 20040722 Opponent name: ALK-ABELLO A/S Effective date: 20040722 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
APAW | Appeal reference deleted |
Free format text: ORIGINAL CODE: EPIDOSDREFNO |
|
APAY | Date of receipt of notice of appeal deleted |
Free format text: ORIGINAL CODE: EPIDOSDNOA2O |
|
APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: STALLERGENES |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60200065 Country of ref document: DE Representative=s name: ISARPATENT PATENTANWAELTE BEHNISCH, BARTH, CHA, DE Ref country code: DE Ref legal event code: R081 Ref document number: 60200065 Country of ref document: DE Owner name: STALLERGENES, FR Free format text: FORMER OWNER: STALLERGENES S.A., 92183 ANTONY, FR Ref country code: DE Ref legal event code: R082 Ref document number: 60200065 Country of ref document: DE Representative=s name: ISARPATENT - PATENTANWAELTE- UND RECHTSANWAELT, DE |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ARNOLD AND SIEDSMA AG, CH Ref country code: CH Ref legal event code: PUE Owner name: STALLERGENES, FR Free format text: FORMER OWNER: STALLERGENES S.A., FR |
|
R26 | Opposition filed (corrected) |
Opponent name: CITEQ B.V. Effective date: 20040722 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20151203 AND 20151209 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: STALLERGENES, FR Effective date: 20160205 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 252314 Country of ref document: AT Kind code of ref document: T Owner name: STALLERGENES, FR Effective date: 20160421 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R064 Ref document number: 60200065 Country of ref document: DE Ref country code: DE Ref legal event code: R103 Ref document number: 60200065 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
RDAF | Communication despatched that patent is revoked |
Free format text: ORIGINAL CODE: EPIDOSNREV1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20180214 Year of fee payment: 17 Ref country code: CH Payment date: 20180214 Year of fee payment: 17 Ref country code: ES Payment date: 20180327 Year of fee payment: 17 Ref country code: DK Payment date: 20180122 Year of fee payment: 17 Ref country code: DE Payment date: 20180212 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PLX |
|
27W | Patent revoked |
Effective date: 20171214 |
|
GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state |
Effective date: 20171214 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20180212 Year of fee payment: 17 Ref country code: BE Payment date: 20180227 Year of fee payment: 17 Ref country code: FR Payment date: 20180126 Year of fee payment: 17 Ref country code: AT Payment date: 20180125 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: PD Owner name: STALLERGENES; FR Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: STALLERGENES S.A. Effective date: 20151012 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20031022 Ref country code: LI Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20031022 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MA03 Ref document number: 252314 Country of ref document: AT Kind code of ref document: T Effective date: 20171214 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20221001 Year of fee payment: 17 |